STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

NCT00623623 | Completed Phase 3 Results

• 2 other identifiers: 1123.282007-001219-44
• Study Type: interventional
• Target: 1,899
• Locations: 16 countries
• Sites: 201

Brief Summary

This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B. The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated. All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.

Conditions

Myocardial Infarction

Outcome Measures

Primary Outcomes (1)

• Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

  The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS).

  30 days

Secondary Outcomes (24)

• Number of Patients With All Cause Mortality

  30 days

• Number of Patients With Cardiac Mortality

  30 days

• Number of Patients With Cardiogenic Shock

  30 days

• Number of Patients With Congestive Heart Failure (CHF)

  30 days

• Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

  30 days

Study Arms (2)

Tenecteplase

EXPERIMENTAL

Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention

Drug: enoxaparin; Procedure: catheterisation; Drug: tenecteplase; Drug: clopidogrel

primary PCI

OTHER

Standard primary PCI

Procedure: primary PCI

Interventions

primary PCI PROCEDURE

Standard primary PCI

primary PCI

enoxaparin DRUG

Adjunctive treatment

Tenecteplase

catheterisation PROCEDURE

Routine or rescue coronary intervention

Tenecteplase

tenecteplase DRUG

Single, weight-adjusted i.v. bolus of tenecteplase

Tenecteplase

clopidogrel DRUG

Adjunctive treatment

Tenecteplase

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age equal or greater than 18 years
• Onset of symptoms \< 3 hours prior to randomisation 3.12-lead ECG indicative of an acute STEMI
• Informed consent received

You may not qualify if:

• Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (201)

1123.28.43009 Boehringer Ingelheim Investigational Site

Salzburg, Austria

Location

1123.28.43010 Boehringer Ingelheim Investigational Site

Salzburg, Austria

Location

1123.28.43001 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43002 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43003 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43004 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43005 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43007 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.43008 Boehringer Ingelheim Investigational Site

Vienna, Austria

Location

1123.28.32060 Boehringer Ingelheim Investigational Site

Bornem, Belgium

Location

1123.28.32010 Boehringer Ingelheim Investigational Site

Brussels, Belgium

Location

1123.28.32070 Boehringer Ingelheim Investigational Site

Herentals, Belgium

Location

1123.28.32040 Boehringer Ingelheim Investigational Site

Liège, Belgium

Location

1123.28.55010 Boehringer Ingelheim Investigational Site

Brasília, Brazil

Location

1123.28.55020 Boehringer Ingelheim Investigational Site

Brasília, Brazil

Location

1123.28.55008 Boehringer Ingelheim Investigational Site

Cabo Frio, Brazil

Location

1123.28.55017 Boehringer Ingelheim Investigational Site

Campinas, Brazil

Location

1123.28.55007 Boehringer Ingelheim Investigational Site

Porto Alegre, Brazil

Location

1123.28.55001 Boehringer Ingelheim Investigational Site

Recife, Brazil

Location

1123.28.55018 Boehringer Ingelheim Investigational Site

Rio de Janeiro, Brazil

Location

1123.28.55028 Boehringer Ingelheim Investigational Site

Rio de Janeiro, Brazil

Location

1123.28.55016 Boehringer Ingelheim Investigational Site

Sao Lourenço Do Sul, Brazil

Location

1123.28.55004 Boehringer Ingelheim Investigational Site

São Paulo, Brazil

Location

1123.28.55014 Boehringer Ingelheim Investigational Site

São Paulo, Brazil

Location

1123.28.11006 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Location

1123.28.11505 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Location

1123.28.11002 Boehringer Ingelheim Investigational Site

Newmarket, Ontario, Canada

Location

1123.28.13001 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.13002 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.13003 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.13004 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.13005 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.13006 Boehringer Ingelheim Investigational Site

Santiago, Chile

Location

1123.28.3376A Boehringer Ingelheim Investigational Site

Ambérieu-en-Bugey, France

Location

1123.28.3329A Boehringer Ingelheim Investigational Site

Aubervilliers, France

Location

1123.28.3329B Boehringer Ingelheim Investigational Site

Aubervilliers, France

Location

1123.28.3329C Boehringer Ingelheim Investigational Site

Aubervilliers, France

Location

1123.28.3315A Boehringer Ingelheim Investigational Site

Besançon, France

Location

1123.28.3315B Boehringer Ingelheim Investigational Site

Besançon, France

Location

1123.28.3351A Boehringer Ingelheim Investigational Site

Besançon, France

Location

1123.28.3351B Boehringer Ingelheim Investigational Site

Besançon, France

Location

1123.28.3302A Boehringer Ingelheim Investigational Site

Bobigny, France

Location

1123.28.3302B Boehringer Ingelheim Investigational Site

Bobigny, France

Location

1123.28.3319A Boehringer Ingelheim Investigational Site

Bordeaux, France

Location

1123.28.3319B Boehringer Ingelheim Investigational Site

Bordeaux, France

Location

1123.28.3319C Boehringer Ingelheim Investigational Site

Bordeaux, France

Location

1123.28.3374A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, France

Location

1123.28.3383A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, France

Location

1123.28.3385A Boehringer Ingelheim Investigational Site

Bourg-en-Bresse, France

Location

1123.28.3347A Boehringer Ingelheim Investigational Site

Bourges, France

Location

1123.28.3347B Boehringer Ingelheim Investigational Site

Bourges, France

Location

1123.28.3347C Boehringer Ingelheim Investigational Site

Bourges, France

Location

1123.28.3355A Boehringer Ingelheim Investigational Site

Bron, France

Location

1123.28.3355B Boehringer Ingelheim Investigational Site

Bron, France

Location

1123.28.3382A Boehringer Ingelheim Investigational Site

Caluire-et-Cuire, France

Location

1123.28.3311A Boehringer Ingelheim Investigational Site

Châteauroux, France

Location

1123.28.3311B Boehringer Ingelheim Investigational Site

Châteauroux, France

Location

1123.28.3346A Boehringer Ingelheim Investigational Site

Châteauroux, France

Location

1123.28.3346B Boehringer Ingelheim Investigational Site

Châteauroux, France

Location

1123.28.3303A Boehringer Ingelheim Investigational Site

Clichy, France

Location

1123.28.3309A Boehringer Ingelheim Investigational Site

Dreux, France

Location

1123.28.3342A Boehringer Ingelheim Investigational Site

Dreux, France

Location

1123.28.3337A Boehringer Ingelheim Investigational Site

Évecquemont, France

Location

1123.28.3387A Boehringer Ingelheim Investigational Site

Fort de France Cedex, France

Location

1123.28.3388A Boehringer Ingelheim Investigational Site

Fort de France Cedex, France

Location

1123.28.3353A Boehringer Ingelheim Investigational Site

Grenoble, France

Location

1123.28.3353B Boehringer Ingelheim Investigational Site

Grenoble, France

Location

1123.28.3317A Boehringer Ingelheim Investigational Site

La Tronche, France

Location

1123.28.3317B Boehringer Ingelheim Investigational Site

La Tronche, France

Location

1123.28.3307A Boehringer Ingelheim Investigational Site

Le Chesnay, France

Location

1123.28.3339A Boehringer Ingelheim Investigational Site

Le Chesnay, France

Location

1123.28.3339B Boehringer Ingelheim Investigational Site

Le Chesnay, France

Location

1123.28.3336A Boehringer Ingelheim Investigational Site

Le Port-Marly, France

Location

1123.28.3301A Boehringer Ingelheim Investigational Site

Lille, France

Location

1123.28.3301B Boehringer Ingelheim Investigational Site

Lille, France

Location

1123.28.3325A Boehringer Ingelheim Investigational Site

Lille, France

Location

1123.28.3325B Boehringer Ingelheim Investigational Site

Lille, France

Location

1123.28.3326A Boehringer Ingelheim Investigational Site

Lille, France

Location

1123.28.3318A Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3318B Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3318C Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3356A Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3356B Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3369A Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3369B Boehringer Ingelheim Investigational Site

Lyon, France

Location

1123.28.3308A Boehringer Ingelheim Investigational Site

Melun, France

Location

1123.28.3308B Boehringer Ingelheim Investigational Site

Melun, France

Location

1123.28.3340A Boehringer Ingelheim Investigational Site

Melun, France

Location

1123.28.3340B Boehringer Ingelheim Investigational Site

Melun, France

Location

1123.28.3379A Boehringer Ingelheim Investigational Site

Montélimar, France

Location

1123.28.3328A Boehringer Ingelheim Investigational Site

Montfermeil, France

Location

1123.28.3328B Boehringer Ingelheim Investigational Site

Montfermeil, France

Location

1123.28.3328C Boehringer Ingelheim Investigational Site

Montfermeil, France

Location

1123.28.3313A Boehringer Ingelheim Investigational Site

Nantes, France

Location

1123.28.3313B Boehringer Ingelheim Investigational Site

Nantes, France

Location

1123.28.3349A Boehringer Ingelheim Investigational Site

Nantes, France

Location

1123.28.3349B Boehringer Ingelheim Investigational Site

Nantes, France

Location

1123.28.3322A Boehringer Ingelheim Investigational Site

Nice, France

Location

1123.28.3322B Boehringer Ingelheim Investigational Site

Nice, France

Location

1123.28.3322C Boehringer Ingelheim Investigational Site

Nice, France

Location

1123.28.3366A Boehringer Ingelheim Investigational Site

Nice, France

Location

1123.28.3375A Boehringer Ingelheim Investigational Site

Oyonnax, France

Location

1123.28.3331A Boehringer Ingelheim Investigational Site

Paris, France

Location

1123.28.3334A Boehringer Ingelheim Investigational Site

Paris, France

Location

1123.28.3371A Boehringer Ingelheim Investigational Site

Paris, France

Location

1123.28.3357A Boehringer Ingelheim Investigational Site

Pessac, France

Location

1123.28.3338A Boehringer Ingelheim Investigational Site

Poissy, France

Location

1123.28.3316A Boehringer Ingelheim Investigational Site

Pringy, France

Location

1123.28.3352A Boehringer Ingelheim Investigational Site

Pringy, France

Location

1123.28.3341A Boehringer Ingelheim Investigational Site

Quincy-sous-Sénart, France

Location

1123.28.3378A Boehringer Ingelheim Investigational Site

Romans-sur-Isère, France

Location

1123.28.3310A Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3310B Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3344A Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3345A Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3345B Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3345C Boehringer Ingelheim Investigational Site

Rouen, France

Location

1123.28.3377A Boehringer Ingelheim Investigational Site

Valence, France

Location

1123.28.3384A Boehringer Ingelheim Investigational Site

Valence, France

Location

1123.28.3373A Boehringer Ingelheim Investigational Site

Vienne, France

Location

1123.28.49002 Boehringer Ingelheim Investigational Site

Berlin, Germany

Location

1123.28.49006 Boehringer Ingelheim Investigational Site

Berlin, Germany

Location

1123.28.49008 Boehringer Ingelheim Investigational Site

Dortmund, Germany

Location

1123.28.49012 Boehringer Ingelheim Investigational Site

Duisburg, Germany

Location

1123.28.49052 Boehringer Ingelheim Investigational Site

Frankenthal, Germany

Location

1123.28.49026 Boehringer Ingelheim Investigational Site

Sömmerda, Germany

Location

1123.28.30012 Boehringer Ingelheim Investigational Site

Alexandroupoli, Greece

Location

1123.28.30001 Boehringer Ingelheim Investigational Site

Athens, Greece

Location

1123.28.30003 Boehringer Ingelheim Investigational Site

Chalikida, Greece

Location

1123.28.30006 Boehringer Ingelheim Investigational Site

Corinth, Greece

Location

1123.28.30011 Boehringer Ingelheim Investigational Site

Katerini, Greece

Location

1123.28.30014 Boehringer Ingelheim Investigational Site

Kavala, Greece

Location

1123.28.30002 Boehringer Ingelheim Investigational Site

Livadeia, Greece

Location

1123.28.30005 Boehringer Ingelheim Investigational Site

Thebes, Greece

Location

1123.28.30007 Boehringer Ingelheim Investigational Site

Thessaloniki, Greece

Location

1123.28.30010 Boehringer Ingelheim Investigational Site

Thessaloniki, Greece

Location

1123.28.30009 Boehringer Ingelheim Investigational Site

Véroia, Greece

Location

1123.28.39201 Boehringer Ingelheim Investigational Site

Ferrara, Italy

Location

1123.28.39002A Boehringer Ingelheim Investigational Site

Genova, Italy

Location

1123.28.39022 Boehringer Ingelheim Investigational Site

Genova, Italy

Location

1123.28.39004A Boehringer Ingelheim Investigational Site

Imperia, Italy

Location

1123.28.39200A Boehringer Ingelheim Investigational Site

Lagosanto (FE), Italy

Location

1123.28.39001A Boehringer Ingelheim Investigational Site

Monza, Italy

Location

1123.28.39011 Boehringer Ingelheim Investigational Site

Monza, Italy

Location

1123.28.39082 Boehringer Ingelheim Investigational Site

Pescia (Pistoia), Italy

Location

1123.28.39083 Boehringer Ingelheim Investigational Site

Pescia (Pistoia), Italy

Location

1123.28.39008A Boehringer Ingelheim Investigational Site

Pistoia, Italy

Location

1123.28.39081 Boehringer Ingelheim Investigational Site

Pistoia, Italy

Location

1123.28.39041 Boehringer Ingelheim Investigational Site

Sanremo (IM), Italy

Location

1123.28.47005 Boehringer Ingelheim Investigational Site

Hamar, Norway

Location

1123.28.47001 Boehringer Ingelheim Investigational Site

Oslo, Norway

Location

1123.28.47002 Boehringer Ingelheim Investigational Site

Oslo, Norway

Location

1123.28.19001 Boehringer Ingelheim Investigational Site

Lima, Peru

Location

1123.28.19004 Boehringer Ingelheim Investigational Site

Lima, Peru

Location

1123.28.48002 Boehringer Ingelheim Investigational Site

Gniezno, Poland

Location

1123.28.48006 Boehringer Ingelheim Investigational Site

Gniezno, Poland

Location

1123.28.48009 Boehringer Ingelheim Investigational Site

Grodzisk Wielopolski, Poland

Location

1123.28.48001 Boehringer Ingelheim Investigational Site

Poznan, Poland

Location

1123.28.70005 Boehringer Ingelheim Investigational Site

Chelyabinsk, Russia

Location

1123.28.77005 Boehringer Ingelheim Investigational Site

Chelyabinsk, Russia

Location

1123.28.70009 Boehringer Ingelheim Investigational Site

Irkutsk, Russia

Location

1123.28.77009 Boehringer Ingelheim Investigational Site

Irkutsk, Russia

Location

1123.28.70002 Boehringer Ingelheim Investigational Site

Kemerovo, Russia

Location

1123.28.77002 Boehringer Ingelheim Investigational Site

Kemerovo, Russia

Location

1123.28.70008 Boehringer Ingelheim Investigational Site

Murmansk, Russia

Location

1123.28.77008 Boehringer Ingelheim Investigational Site

Murmansk, Russia

Location

1123.28.77003 Boehringer Ingelheim Investigational Site

Nizhny Novgorod, Russia

Location

1123.28.70003 Boehringer Ingelheim Investigational Site

Nizhnyi Novgorod, Russia

Location

1123.28.70006 Boehringer Ingelheim Investigational Site

Saint Petersburg, Russia

Location

1123.28.70007 Boehringer Ingelheim Investigational Site

Saint Petersburg, Russia

Location

1123.28.77006 Boehringer Ingelheim Investigational Site

Saint Petersburg, Russia

Location

1123.28.70004 Boehringer Ingelheim Investigational Site

Tomsk, Russia

Location

1123.28.77004 Boehringer Ingelheim Investigational Site

Tomsk, Russia

Location

1123.28.70001 Boehringer Ingelheim Investigational Site

Yekaterinburg, Russia

Location

1123.28.77001 Boehringer Ingelheim Investigational Site

Yekaterinburg, Russia

Location

1123.28.38101 Boehringer Ingelheim Investigational Site

Belgrade, Serbia

Location

1123.28.38103 Boehringer Ingelheim Investigational Site

Belgrade, Serbia

Location

1123.28.38104 Boehringer Ingelheim Investigational Site

Belgrade, Serbia

Location

1123.28.38106 Boehringer Ingelheim Investigational Site

Niš, Serbia

Location

1123.28.38107 Boehringer Ingelheim Investigational Site

Niš, Serbia

Location

1123.28.38108 Boehringer Ingelheim Investigational Site

Smederevo, Serbia

Location

1123.28.38109 Boehringer Ingelheim Investigational Site

Šabac, Serbia

Location

1123.28.38110 Boehringer Ingelheim Investigational Site

Vršac, Serbia

Location

1123.28.38111 Boehringer Ingelheim Investigational Site

Zaječar, Serbia

Location

1123.28.38104 Boehringer Ingelheim Investigational Site

Zemun, Serbia

Location

1123.28.38105 Boehringer Ingelheim Investigational Site

Zemun, Serbia

Location

1123.28.34001 Boehringer Ingelheim Investigational Site

Almería, Spain

Location

1123.28.34004 Boehringer Ingelheim Investigational Site

Granada, Spain

Location

1123.28.34003 Boehringer Ingelheim Investigational Site

Huelva, Spain

Location

1123.28.34007 Boehringer Ingelheim Investigational Site

Madrid, Spain

Location

1123.28.34002 Boehringer Ingelheim Investigational Site

Málaga, Spain

Location

1123.28.34011 Boehringer Ingelheim Investigational Site

Salamanca, Spain

Location

1123.28.44600 Boehringer Ingelheim Investigational Site

Belfast, United Kingdom

Location

1123.28.44610 Boehringer Ingelheim Investigational Site

Belfast, United Kingdom

Location

1123.28.44210 Boehringer Ingelheim Investigational Site

Bristol, United Kingdom

Location

1123.28.44220 Boehringer Ingelheim Investigational Site

Bristol, United Kingdom

Location

1123.28.44200 Boehringer Ingelheim Investigational Site

Chippenham, United Kingdom

Location

1123.28.44620 Boehringer Ingelheim Investigational Site

Dundonald, United Kingdom

Location

1123.28.44110 Boehringer Ingelheim Investigational Site

Leicester, United Kingdom

Location

1123.28.44630 Boehringer Ingelheim Investigational Site

Newry, United Kingdom

Location

1123.28.44100 Boehringer Ingelheim Investigational Site

Nottingham, United Kingdom

Location

Related Publications (11)

• Armstrong PW, Zheng Y, Welsh RC, Sinnaeve PR, de Werf FV, Westerhout CM, Bainey KR. Primary Percutaneous Coronary Intervention within the First Hour: Insights from Early-Treated Patients with ST-Elevation Myocardial Infarction. Am Heart J. 2026 Jan 29:107363. doi: 10.1016/j.ahj.2026.107363. Online ahead of print.

  PMID: 41619999 DERIVED

• Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Temple T, Ly E, Bogaerts K, Sinnaeve P, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators. Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials. Am Heart J. 2025 Jun;284:20-31. doi: 10.1016/j.ahj.2025.02.002. Epub 2025 Feb 12.

  PMID: 39952376 DERIVED

• Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Music LB, Temple T, Ly E, Bogaerts K, Sinnaeve PR, Danays T, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators. Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged >/=75 Years in STREAM-1 and 2. Circ Cardiovasc Interv. 2024 Dec;17(12):e014251. doi: 10.1161/CIRCINTERVENTIONS.124.014251. Epub 2024 Dec 17.

  PMID: 39689189 DERIVED

• Shavadia J, Welsh R, Gershlick A, Zheng Y, Huber K, Halvorsen S, Steg PG, Van de Werf F, Armstrong PW. Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. J Am Heart Assoc. 2016 Jun 13;5(6):e003559. doi: 10.1161/JAHA.116.003559.

  PMID: 28525886 DERIVED

• Bainey KR, Fresco C, Zheng Y, Halvorsen S, Carvalho A, Ostojic M, Goldstein P, Gershlick AH, Westerhout CM, Van de Werf F, Armstrong PW; STREAM Investigators. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. Heart. 2016 Apr;102(7):527-33. doi: 10.1136/heartjnl-2015-308075. Epub 2016 Jan 18.

  PMID: 26783237 DERIVED

• Shavadia J, Zheng Y, Dianati Maleki N, Huber K, Halvorsen S, Goldstein P, Gershlick AH, Wilcox R, Van de Werf F, Armstrong PW. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015 Aug 24;4(8):e002049. doi: 10.1161/JAHA.115.002049.

  PMID: 26304934 DERIVED

• Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart. 2015 May;101(9):692-8. doi: 10.1136/heartjnl-2014-306686. Epub 2015 Feb 17.

  PMID: 25691510 DERIVED

• Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26.

  PMID: 25161043 DERIVED

• Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014 Oct;100(19):1543-9. doi: 10.1136/heartjnl-2014-306023. Epub 2014 Jun 10.

  PMID: 24916050 DERIVED

• Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10.

  PMID: 23473396 DERIVED

• Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010 Jul;160(1):30-35.e1. doi: 10.1016/j.ahj.2010.04.007.

  PMID: 20598969 DERIVED

MeSH Terms

Conditions

Myocardial Infarction

Interventions

Enoxaparin; Catheterization; Tenecteplase; Clopidogrel

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis

Intervention Hierarchy (Ancestors)

Heparin, Low-Molecular-Weight; Heparin; Glycosaminoglycans; Polysaccharides; Carbohydrates; Therapeutics; Investigative Techniques; Tissue Plasminogen Activator; Serine Endopeptidases; Endopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Serine Proteases; Plasminogen Activators; Blood Coagulation Factors; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Ticlopidine; Thienopyridines; Thiophenes; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Results Point of Contact

• Title: Boehringer Ingelheim, Call Center
• Organization: Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

Study Officials

• Boehringer Ingelheim

  Boehringer Ingelheim

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 15, 2008
• First Posted: February 26, 2008
• Study Start: March 1, 2008
• Primary Completion: September 1, 2012
• Study Completion: September 1, 2012
• Last Updated: August 1, 2019
• Results First Posted: August 1, 2019

Record last verified: 2019-06

Locations

FR (87); BR (11); GB (9); PE (2); AU (9); DE (6); CA (3); SE (11); IT (12); NO (3); CL (6); ES (6); PL (4); BE (4); RU (17); GR (11)